Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249. (Q51281037)
Jump to navigation
Jump to search
scientific article published in November 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249. |
scientific article published in November 2016 |
Statements
1 reference
Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249. (English)
1 reference
Sweety Agrawal
1 reference
1 November 2016
1 reference
1 reference
39
1 reference
e198
1 reference
11
1 reference
Identifiers
1 reference
1 reference